Gyros Protein Technologies AB

Gyros Protein Technologies is a leading provider of peptide synthesis and bioanalytical tools

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

AFTER BAGGING $200M-PLUS IN 2019, PASSAGE BIO GUNS FOR $125M IPO

FierceBiotech | February 04, 2020

news image

Despite pulling off two megarounds in 2019, Passage Bio is returning to the funding well—but this time, it’s going public. The company filed for a $125 million IPO, which will bankroll the development of its three lead gene therapy programs in dementia, Krabbe disease and rare childhood disease GM1 gangliosidosis. Those programs were among five that Passage picked up in its partnership with the University of Pennsylvania’s Gene Therapy Program in February 2019. At the sam...

Read More

INDUSTRIAL IMPACT

LUMMUS AND SYNTHOS ADVANCE BIO-BUTADIENE TECHNOLOGY DEVELOPMENT TO PRODUCE SUSTAINABLE RUBBER

Lummus Technology, LLC | February 14, 2022

news image

Lummus Technology announced that its Green Circle business and Synthos S.A. have reached a major milestone in the development of advanced bio-butadiene technology. After completing a successful feasibility study in 2021, Lummus and Synthos have concluded that the bio-butadiene technology is ready for implementation, and the companies have agreed to move into the engineering and design phase of the project. Given the confidence in the technology and the strong market demand for ren...

Read More

BIOTECHS WORKING CLOSELY & FEVERISHLY WITH CDC FOR COVID-19 VACCINE DEVELOPMENT

PR Newswire | April 07, 2020

news image

Many companies searching for an effective therapy or vaccine for the present world health crisis are focusing on creating a vaccine from the immune system. Key to the race to develop a vaccine for the new coronavirus is a technology that uses the virus' genetic code to essentially persuade your body to make its own vaccine. This technique is faster than egg-based manufacturing, which produces the majority of annual flu vaccines… And it's enabling a possible vaccine for the new cor...

Read More

REGENERON STARTS PHASE REGN-COV2 PHASE 3 COVID-19 PREVENTION TRIAL

Regeneron | July 07, 2020

news image

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the initiation of late-stage clinical trials evaluating REGN-COV2, Regeneron's investigational double antibody cocktail for the treatment and prevention of COVID-19. A Phase 3 trial will evaluate REGN-COV2's ability to prevent infection among uninfected people who have had close exposure to a COVID-19 patient (such as the patient's housemate), and is being run jointly with the National Institute of Allergy and Infectious ...

Read More
news image

AFTER BAGGING $200M-PLUS IN 2019, PASSAGE BIO GUNS FOR $125M IPO

FierceBiotech | February 04, 2020

Despite pulling off two megarounds in 2019, Passage Bio is returning to the funding well—but this time, it’s going public. The company filed for a $125 million IPO, which will bankroll the development of its three lead gene therapy programs in dementia, Krabbe disease and rare childhood disease GM1 gangliosidosis. Those programs were among five that Passage picked up in its partnership with the University of Pennsylvania’s Gene Therapy Program in February 2019. At the sam...

Read More
news image

INDUSTRIAL IMPACT

LUMMUS AND SYNTHOS ADVANCE BIO-BUTADIENE TECHNOLOGY DEVELOPMENT TO PRODUCE SUSTAINABLE RUBBER

Lummus Technology, LLC | February 14, 2022

Lummus Technology announced that its Green Circle business and Synthos S.A. have reached a major milestone in the development of advanced bio-butadiene technology. After completing a successful feasibility study in 2021, Lummus and Synthos have concluded that the bio-butadiene technology is ready for implementation, and the companies have agreed to move into the engineering and design phase of the project. Given the confidence in the technology and the strong market demand for ren...

Read More
news image

BIOTECHS WORKING CLOSELY & FEVERISHLY WITH CDC FOR COVID-19 VACCINE DEVELOPMENT

PR Newswire | April 07, 2020

Many companies searching for an effective therapy or vaccine for the present world health crisis are focusing on creating a vaccine from the immune system. Key to the race to develop a vaccine for the new coronavirus is a technology that uses the virus' genetic code to essentially persuade your body to make its own vaccine. This technique is faster than egg-based manufacturing, which produces the majority of annual flu vaccines… And it's enabling a possible vaccine for the new cor...

Read More
news image

REGENERON STARTS PHASE REGN-COV2 PHASE 3 COVID-19 PREVENTION TRIAL

Regeneron | July 07, 2020

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the initiation of late-stage clinical trials evaluating REGN-COV2, Regeneron's investigational double antibody cocktail for the treatment and prevention of COVID-19. A Phase 3 trial will evaluate REGN-COV2's ability to prevent infection among uninfected people who have had close exposure to a COVID-19 patient (such as the patient's housemate), and is being run jointly with the National Institute of Allergy and Infectious ...

Read More